Faron Pharmaceuticals Oy Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Faron Pharmaceuticals Oy şirketinin toplam hissedar öz sermayesi €1.4M ve toplam borcu €12.4M olup, bu da borç-öz sermaye oranını 897.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €35.5M ve €34.1M dir.

Anahtar bilgiler

897.6%

Borç/özkaynak oranı

€12.38m

Borç

Faiz karşılama oranı	n/a
Nakit	€29.98m
Eşitlik	€1.38m
Toplam yükümlülükler	€34.08m
Toplam varlıklar	€35.46m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: FARON 'nin kısa vadeli varlıkları ( €34.0M ) kısa vadeli yükümlülüklerini ( €23.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: FARON şirketinin kısa vadeli varlıkları ( €34.0M ) uzun vadeli yükümlülüklerini ( €10.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: FARON şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: FARON şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: FARON şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: FARON serbest nakit akışı her yıl % 6 1.5 yıl yetecek nakit akışına sahip olacaktır.

Faron Pharmaceuticals Oy Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Faron Pharmaceuticals Ltd Announces Events of Default

Recent updates

Faron Pharmaceuticals Ltd. Announces FDA Grants Fast Track Designation for Bexmarilimab

Faron Pharmaceuticals Ltd. Appoints Yrjö Wichmann as Permanent Chief Financial Officer

Faron Pharmaceuticals Ltd. Announces Changes to Management Team, August 15, 2024

Faron Pharmaceuticals Ltd. Announces Positive FDA Feedback

Faron Pharmaceuticals Oy Announces Chief Executive Officer Changes

Faron Pharmaceuticals Oy Announces Chief Financial Officer Changes

Faron Pharmaceuticals Oy Confirms Plans for the Coming Months

Faron Pharmaceuticals Ltd. Announces Chief Executive Officer Changes

Faron Pharmaceuticals Ltd. Announces Additional Positive Data from the Phase 1 Part of the Bexmab Study in Both Higher-Risk HMA-Failed MDS and r/r AML

Faron Pharmaceuticals Oy Announces Board Changes

Faron Pharmaceuticals Oy announced that it expects to receive €3.2 million in funding

Faron Pharmaceuticals Ltd Announces Events of Default

Faron Pharmaceuticals Ltd. Provides Details from Its Further Analysis of Data from the Completed Phase 1 Part of the Ongoing Bexmab Trial

Faron Pharmaceuticals Ltd. Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial

Faron Pharmaceuticals Oy to Report Fiscal Year 2023 Results on Feb 29, 2024

Faron Pharmaceuticals Ltd. Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology Annual Meeting

New major risk - Share price stability

Faron Pharmaceuticals Oy Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine

New minor risk - Profitability

Faron Pharmaceuticals Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-Failed MDS

Faron Pharmaceuticals Oy has completed a Follow-on Equity Offering in the amount of €7.102194 million.

New major risk - Financial position

Faron Announces Positive BEXMAB Study Update

Less than half of directors are independent

Faron Pharmaceuticals Ltd. Announces Board Changes

Faron Pharmaceuticals Ltd Appoints Birge Berns as Interim Chief Medical Officer

Faron Pharmaceuticals Oy Announces Change in the Board of Directors

New minor risk - Share price stability

Faron Pharmaceuticals Ltd. Announces New Positive Clinical Data from the Ongoing Phase I/II BEXMAB Study

Faron Pharmaceuticals Oy Announces New Biomarker Data from BEXMAB Study at EHA2023

Faron Pharmaceuticals Oy Announces Executive Changes

Forecast to breakeven in 2025

Faron Pharmaceuticals Oy has completed a Follow-on Equity Offering in the amount of €12.000001 million.

Faron Pharmaceuticals Oy Announces Objective Responses in 3 Out of 5 Patients Dosed in the First Doublet Cohort of Phase I/Ii Bexmab Study

Faron Pharmaceuticals Oy to Report First Half, 2023 Results on Aug 29, 2023

Faron Pharmaceuticals Oy, Annual General Meeting, Mar 24, 2023

Faron Pharmaceuticals Oy Announces Bexmab Study Update

Faron Pharmaceuticals Oy Appoints Maija Hollmén as Chief Scientific Officer

Price target decreased to €2.50

Faron Pharmaceuticals Announces Poster Presentation of Targeted Immunotherapy Bexmarilimab at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

High number of new directors

Faron Pharmaceuticals Oy Announces Dosing Moves to Second Level in its Phase I/II BEXMAB Study

Faron Pharmaceuticals Ltd Announces Melanoma Cohort Data from Matins

Faron Pharmaceuticals Oy has completed a Follow-on Equity Offering in the amount of €8.402201 million.

Faron Pharmaceuticals Oy Announces Top-Line Data on Bexmarilimab Dose Variation

Faron Pharmaceuticals Oy Announces Traumakine Data on Multi-Organ Dysfunction and Limb Salvage to Be Presented at the Military Health System Research Symposium

Faron Announces Top-Line 12-Month Survival Results

Faron Pharmaceuticals Doses First Patient in Phase I/II font-family

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

High number of new directors

Faron Pharmaceuticals Ltd Announces Management Changes

Faron Presents Results from Melanoma Cohort of MATINS Trial at 18th Congress of the European Association of Dermato-Oncology (EADO)

Faron Closes HIBISCUS Trial Due to Low COVID-19 Infection and Hospitalization Rates in the US and Reverts Resources to the Development of Bexmarilimab

Faron Pharmaceuticals Oy announced that it expects to receive €30 million in funding from IPF Management S.A

Faron Pharmaceuticals Oy Updates on Bexmarilimab Development Program

Faron Pharmaceuticals Ltd Announces Scientific Reports Publishes INFORAAA Results Showing Traumakine-Induced Up-Regulation of CD73

Faron Pharmaceuticals Ltd Announces the Appointment of Juho Jalkanen, M.D., Ph.D., as Chief Operating Officer

Faron Announces Topline MATINS Biomarker Analysis

Chief Medical Officer & VP of Drug Development Matti Karvonen has left the company

High number of new directors

Faron Pharmaceuticals Doses First Patient in Phase II/III HIBISCUS Trial of Traumakine for Treatment of Hospitalized COVID-19 Patients

Faron Pharmaceuticals Oy Announces First-In-Human Bexmarilimab Results Published in Clinical Cancer Research

Faron Pharmaceuticals Oy Announces Promising New Data from Its Ongoing Bexmarilimab MATINS Study

Faron Pharmaceuticals Oy has completed a Follow-on Equity Offering in the amount of €15.000001 million.

Faron Pharmaceuticals Oy Announces U.S. Food and Drug Administration Approve the Phase II/III HIBISCUS trial assessing Traumakine

Faron Pharmaceuticals Oy Announces New Observations from Ongoing Matins Trial and an Update on the Study

New 90-day high: €3.95

New 90-day low: €3.00

Faron Pharmaceuticals Oy to Report First Half, 2021 Results on Aug 26, 2021

Faron Pharmaceuticals Oy Provides Bexmarilimab (Clevegen) Development Update

New 90-day low: €3.02

New 90-day low: €4.02

Faron Pharmaceuticals Oy Announces First Results from WHO Solidarity Trial

Faron Pharmaceuticals Ltd Announces That MATINS Trial Data Presented at ESMO